Video Experimental Relacionado
Updated: Jan 8, 2026
11:13
Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment
Published on: June 9, 2023
2.2K
Nuevos compuestos como inhibidores de PI3Kalpha para el tratamiento del cáncer
1Arclin USA LLC, 1150 Sanctuary Parkway, Suite 100, Alpharetta, Georgia 30009, United States.
ACS medicinal chemistry letters
|December 17, 2025
Resumen
Se presentan nuevos compuestos que inhiben la fosfoinositida 3-quinasa alfa (PI3Kα). Estos compuestos ofrecen nuevas estrategias terapéuticas para el tratamiento de diversas formas de cáncer.
Área de la Ciencia:
- Química Medicinal
- Oncología
- Farmacología
Sus antecedentes:
- La vía PI3K/AKT/mTOR está frecuentemente desregulada en el cáncer, impulsando el crecimiento y la supervivencia tumoral.
- PI3Kα es una isoforma clave dentro de esta vía, lo que la convierte en un objetivo terapéutico atractivo.
- El desarrollo de inhibidores selectivos de PI3Kα es crucial para un tratamiento eficaz del cáncer con efectos fuera del objetivo reducidos.
Objetivo del estudio:
- Revelar nuevas entidades químicas con potente actividad inhibidora de PI3Kα.
- Presentar composiciones farmacéuticas que comprenden estos nuevos inhibidores de PI3Kα.
- Esbozar la utilidad de estos compuestos en el tratamiento del cáncer.
Principales métodos:
- Síntesis y caracterización de nuevos compuestos químicos.
- Evaluación in vitro de la potencia y selectividad de la inhibición de PI3Kα.
- Evaluación de la actividad anticancerígena en modelos celulares y/o animales relevantes.
Principales resultados:
- Identificación de nuevos compuestos que demuestran una inhibición significativa de PI3Kα.
- Demostración de efectos antiproliferativos y/o citotóxicos de estos compuestos contra células cancerosas.
- Establecimiento de rutas sintéticas para la preparación de estos nuevos inhibidores.
Conclusiones:
- Los nuevos inhibidores de PI3Kα representan una nueva clase prometedora de agentes anticancerígenos.
- Estos compuestos tienen el potencial de desarrollarse en terapias eficaces para cánceres dependientes de PI3Kα.
- Se justifica un mayor desarrollo preclínico y clínico para explorar su potencial terapéutico.
Videos de Conceptos Relacionados
01:22PI3K/mTOR/AKT Signaling Pathway
5.3K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
5.3K
02:34Inhibition of Cdk Activity
5.5K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.5K
02:57Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
02:50Combination Therapies and Personalized Medicine
5.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.8K
01:15Drugs that Stabilize Microtubules
2.6K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.6K
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
436
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
436